Skip to main content
. 2021 Aug 24;22(17):9116. doi: 10.3390/ijms22179116

Table 1.

Demographics and hepatitis B virus status of 118 patients with SLE.

Demographics All HBsAg-Positive Resolved HBV p-Value
N = 118 N = 55 N = 63
Age at diagnosis of SLE (years) 35.2 ± 14.7 37.0 ± 15.2 33.6 ± 14.2 0.213
Female 97 (82.2) 44 (80.0) 53 (84.1) 0.559
Baseline ALT (IU/mL) 23.4 ± 12.3 25.0 ± 12.3 22.1 ± 12.2 0.200
Baseline AST (IU/mL) 24.7 ± 10.3 26.3 ± 10.5 23.4 ± 10.0 0.125
Baseline total bilirubin (mg/dL) 0.42 ± 0.19 0.45 ± 0.19 0.40 ± 0.19 0.166
HBeAg-positive 10/64 (15.6) 10/47 (21.3) 0/17 (0.0) -
Anti-HBs positive 50 (42.4) 0 (0.0) 50 (79.4) -
Immunologic profiles
ANA titer > 1:80 118 (100.0) 55 (100.0) 63 (100.0) -
Anti-SSA/Ro positive 50/94 (53.2) 17/42 (40.5) 33/52 (63.5) 0.026 *
Anti-SSB/La positive 17/89 (19.1) 5/41 (12.2) 12/48 (25.0) 0.120
Anti-Smith positive 11/78 (14.1) 2/39 (5.1) 9/39 (23.1) 0.018 *
Anti-RNP positive 23/74 (31.1) 7/36 (19.4) 16/38 (42.1) 0.028 *
Anti-dsDNA positive 105 (89.0) 47 (85.5) 58 (92.1) 0.252
Clinical manifestations
Hematologic disorder 81 (68.6) 34 (61.8) 47 (74.6) 0.174
Kidney involvement 49 (41.5) 20 (36.4) 29 (46.0) 0.287
CNS involvement 20 (16.9) 10 (18.2) 10 (15.9) 0.739
Psychosis 4 (3.4) 2 (3.6) 2 (3.2) 0.890
Serositis 13 (11.0) 7 (12.7) 6 (14.3) 0.580
Joint involvement 86 (72.9) 37 (67.3) 49 (77.8) 0.201
Skin involvement 105 (89.0) 47 (85.5) 58 (92.1) 0.252
Follow up (years) 15.4 ± 10.3 11.7 ± 9.4 18.6 ± 10.2 <0.001 *

Abbreviations: ANA, anti-nuclear antibody; anti-HBs, antibody to hepatitis B surface antigen; CNS, central nervous system; dsDNA, double-stranded DNA; HBeAg, hepatitis B virus e antigen; HBsAg, hepatitis B surface antigen; RNP, ribonucleoprotein. Data are presented as frequency (percentage) or mean ± standard deviation. * p < 0.05.